Brief: Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy
23/09/2026 11:06
BRIEF-Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy Sept 23 (Reuters) - Cardiol Therapeutics Inc CRDL.TO:
CARDIOL THERAPEUTICS ACHIEVES PHASE III MAVERIC ENROLLMENT TARGET AHEAD OF SCHEDULE AND EXPANDS PIVOTAL TRIAL TO STRENGTHEN ASSESSMENT OF CARDIOLRX™'S EFFICACY
Source text: ID:nCNWgZ9P5a
Further company coverage: CRDL.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiol Therapeutics
See all newsBrief: Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy
Brief: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus
Brief: Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM